Latest Long-term nonprogressor Stories
Data Demonstrate Cytoxan Preconditioning Combined with CD4/CD8 ZFN-modified T-cell Product Reduces Viral Load to Limit of Quantification in One Subject of Three; Delays Onset of Viremia in Another
New findings inform prevention, treatment and cure research and development NEW YORK, Feb.
Phase I Trial Reveals DNA Immunotherapy Results Were Similar To HIV-Infected Patients Whose Disease Did Not Progress PLYMOUTH MEETING, Pa., Jan.
RICHMOND, Calif., Oct. 16, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
Control of Viral Load During Treatment Interruption of Antiretroviral Therapy Sustained and Ongoing for More than One Year in One Subject and Several Months in Another RICHMOND,
A man infected by HIV-1 in 1998 was treated at the time of acute infection with 4 antiretrovirals during 2 years and is now still in remission TOULON, France, Aug.
People infected with HIV whose immune cells have low cholesterol levels experience much slower disease progression, even without medication.
Drug resistance mutations in HIV reduce the genetic diversity in the rest of the virus genome when they spread within an infected patient, but they do so to a different extent in different patients.
Researchers at the UNC School of Medicine have deployed a potential new weapon against HIV – a combination therapy that targets HIV-infected cells that standard therapies cannot kill.
People with human immunodeficiency virus (HIV) run a higher risk of virologic failure than previously thought, even when their number of RNA copies of the retrovirus per millilitre of blood is slightly above the detection threshold.
- A hairdresser.